ArticleFrontiers in endocrinology2025
Multimodal radiomics model with triple -timepoint contrast-enhanced ultrasound for precise diagnosis of C-TIRADS 4 thyroid nodules.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence in thyroid ultrasound: clinical applications and perspectives.Frontiers in endocrinology · 2026Review
- Integration of BRAF V600E mutation with contrast-enhanced ultrasound parameters provides complementary diagnostic value for malignant thyroid nodules.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to construct a multimodal radiomics model based on contrast-enhanced ultrasound (CEUS) radiomic features, combined with conventional ultrasonography (US) images and clinical data, to evaluate its diagnostic efficacy in differentiating benign and malignant thyroid nodules (TNs) classified as C-TIRADS 4, and to assess the clinical application value of the model. Methods: This retrospective study enrolled 135 patients with C-TIRADS 4 thyroid nodules who underwent concurrent US and CEUS before FNA/surgery. From each case, one US image and three CEUS key frames (2s post-perfusion, peak enhancement, 2s post-peak) were selected. Patients were randomly split into training (n=108) and test (n=27) cohorts (8:2 ratio). ROIs were manually delineated (3D-Slicer), with radiomics features extracted (PyRadiomics) and selected via mRMR and LASSO. Six CEUS radiomics-based machine learning models (KNN, SVM, RF, XGBoost, LightGBM, SGD) were developed and evaluated using AUC, accuracy, sensitivity, specificity, and F1-score. The optimal classifier was used to build US-only, US+CEUS, and clinical+US+CEUS models. Statistical comparisons employed DeLong tests, calibration curves, and DCA. Results: The CEUS radiomics model demonstrated favorable diagnostic performance in differentiating benign and malignant C-TIRADS 4 thyroid nodules, with sensitivity, specificity, and accuracy of 0.875, 0.769, and 0.833, respectively. When CEUS radiomic features were combined with US features, the diagnostic performance of the CEUS radiomics model was comparable to that of the US+CEUS radiomics model (AUC: 0.813 vs. 0.829, P=0.005). Furthermore, the multimodal radiomics model integrating clinical data (clinical+US+CEUS radiomics model) achieved significantly improved diagnostic efficacy, with an AUC of 0.967, along with accuracy, sensitivity, specificity, and F1-score values of 0.815, 0.823, 0.792, and 0.884, respectively. Conclusion: Our study developed a high-performance multimodal diagnostic model through the innovative integration of radiomic features from three critical CEUS timepoints combined with conventional ultrasound and clinical data, establishing a novel decision-support tool for accurate noninvasive classification of C-TIRADS 4 thyroid nodules. The model's superior diagnostic performance (AUC 0.967) demonstrates the transformative potential of multimodal integration in overcoming single-modality limitations and enhancing clinical decision-making, positioning this approach as a promising solution to mitigate unnecessary diagnostic procedures and overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.